News

Capricor Therapeutics Set to Announce Q4 2024 Financial Results

Capricor Therapeutics Set to Announce Q4 2024 Financial Results

Anticipating Financial Updates from Capricor Therapeutics

Capricor Therapeutics, Inc. (NASDAQ: CAPR), a promising biotechnology company focused on cell and exosome-based therapies, is gearing up to share significant financial updates. The firm has announced that it will release its financial results for the fourth quarter and full fiscal year ending December 31, 2024, on an anticipated date in March.

Key Event Details

The announcement is expected to take place following market closure on March 19, 2025. The company's management has scheduled a conference call and webcast for 4:30 p.m. ET that same day. This event will provide shareholders and interested parties with a comprehensive understanding of Capricor's financial performance and any recent corporate developments.

How to Join the Conference Call

For those interested in participating, the conference call can be accessed using the following information: it will be toll-free for U.S. callers at 1-800-717-1738, and international participants can join by dialing 1-646-307-1865. Additionally, the conference ID is 98172, making it easy for attendees to connect.

The Role of Deramiocel in Capricor's Future

At the heart of Capricor's research and development efforts is its lead product candidate, deramiocel. This innovative cell therapy has been designed to combat rare diseases such as Duchenne muscular dystrophy. Current clinical studies are promising, suggesting that deramiocel could offer significant benefits by demonstrating immunomodulatory, antifibrotic, and regenerative properties. Capricor is hopeful about deramiocel's potential to change lives and enhance the treatment landscape.

Exploring Exosome Technology

Beyond deramiocel, Capricor’s dedication to exploring advanced technologies is evident in its proprietary StealthX™ platform. This innovative approach leverages exosomes for targeted therapeutic delivery, aiming to revolutionize how diseases are treated and prevented. The potential applications encompass a broad spectrum, including vaccine development and the precise delivery of oligonucleotides and proteins.

Commitment to Advancement

Capricor Therapeutics is firmly committed to expanding its capabilities and fostering breakthrough therapies to address unmet medical needs. The ongoing support from stakeholders is essential as the company navigates the complexities of clinical trials and regulatory approvals.

Staying Informed with Follow-Up

For those unable to attend the live session, a replay of the webcast will be made available shortly after the event, ensuring that stakeholders can stay informed about Capricor's developments and financial results.

About Capricor Therapeutics

Capricor Therapeutics, Inc. is at the forefront of biotechnological innovation. With a passionate focus on cell therapy and exosome technology, it strives to push the boundaries of medical science in the realm of rare diseases. By continually developing promising therapies like deramiocel, Capricor aims to create transformative solutions for patients in dire need of effective treatments.

Key Contact Information

For media inquiries, Capricor’s media contact is Raquel Cona at KCSA Strategic Communications. She can be reached at rcona@kcsa.com or by phone at 212.896.1204. Moreover, AJ Bergmann, the Chief Financial Officer, is available for company-related questions at abergmann@capricor.com, with a direct line at 858.727.1755.

Frequently Asked Questions

1. When will Capricor Therapeutics announce their financial results?

The financial results are scheduled to be announced after market closure on March 19, 2025.

2. How can I participate in the conference call?

You can join the call by dialing 1-800-717-1738 in the U.S. or 1-646-307-1865 internationally, using conference ID 98172.

3. What is deramiocel, and why is it important?

Deramiocel is Capricor's lead product candidate, significant for treating Duchenne muscular dystrophy through its unique cell therapy approach.

4. How is Capricor investing in exosome technology?

The company utilizes its StealthX™ platform to enhance the targeted delivery of therapies, including vaccines and proteins, marking a novel approach in treatment strategies.

5. Where can I find more information about Capricor?

Additonally, more information can be found on their official website at capricor.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Greenberg Traurig Builds Real Estate Bench Further

Updated Category News Views 71

Two real estate lawyers rarely move a market, but they can tell you where the legal work is getting sticky. Greenberg Traurig’s November 19 addition of Steven A. Fein and Kelsey Thayer is not some grand macroeconomic pronouncement, and nobody should pretend otherwise. It is, however, a pretty sensible read on the messy corners of commercial property finance: joint...

Continue Reading
Hydron’s Bailey Test Puts RNG Cost Claims to Real Work

Updated Category News Views 55

Landfill gas is messy stuff, which is exactly why Hydron Energy’s Bailey Landfill demonstration in Chilliwack deserves more attention than another clean-energy press release. The British Columbia company is putting its INTRUPTor™ gas-separation system into an operating environment alongside FortisBC and the City of Chilliwack, where the machinery has to deal with real...

Continue Reading
Lecanemab's Alpha-Syn Signal Deserves a Cooler Head

Updated Category News Views 108

Mixed pathology is where Alzheimer's investing gets uncomfortably real, and this new lecanemab readout is a decent reminder that a drug can show promise without settling the argument. Eisai and Biogen presented a Clarity AD cerebrospinal-fluid substudy at CTAD 2026 examining people with early Alzheimer's disease who also tested positive for alpha-synuclein pathology. The...

Continue Reading
Birkenstock’s Athens Stores Put Brand Control to Work

Updated Category News Views 41

A 62-square-meter shop on Ermou Street can say plenty about a brand’s ambitions. Birkenstock is opening its first two Greek stores in Athens, moving beyond its existing wholesale and retail-partner presence with locations it can shape from the floorboards up. The first site at Ermou 18 is stated to have opened on November 12, 2026; the announcement itself is dated...

Continue Reading
AbbaDox Finds Follow-Up Scans Lost in the Shuffle

Updated Category News Views 163

A six-month recommendation has a nasty habit of disappearing beneath today’s emergencies. That is the unglamorous, important problem AbbaDox is trying to solve in outpatient radiology: not reading the scan, but making sure a future scan recommendation actually gets reviewed, ordered, and scheduled. For investors watching healthcare operations software, this is the sort...

Continue Reading
Central Florida Buyers Face the Cash Reality First

Updated Category News Views 44

A house hunt can go sideways before the first showing if the buyer has confused a dream budget with a real one. Tom McKnight’s guidance for first-time buyers in Central Florida lands on the unglamorous stuff, which is exactly where it ought to land: cash, credit, financing, insurance, taxes, and the physical condition of the house. Nobody enjoys staring at lender...

Continue Reading
West Virginia SEO Timelines Demand Patience, Not Hype

Updated Category News Views 54

A fresh website with no search footprint is not a race car; it is a pickup stuck in mud, and Sean O'Kelly's view of local SEO in West Virginia puts that inconvenient fact right on the table. Most businesses can expect measurable improvement after three to six months of consistent work, according to the HelloNation article. That is not a glamorous answer, but it is the...

Continue Reading
Visa CEDP Data Gaps Are Quietly Hammering Merchants

Updated Category News Views 100

Somewhere between a checkout button and settlement, an awful lot of money is apparently falling through a trapdoor. Verisave and Canyon Payments say 93% of the 180 merchant accounts they reviewed during one month missed Visa Commercial Enhanced Data Program discounts they could have received. The claimed savings left on the table topped $800,000 for that group in that...

Continue Reading
RingConn Bets Middle-earth Fandom Can Boost Health Wearables

Updated Category News Views 30

A Familiar Gold Band Meets a Crowded Wearables Market RingConn has taken one of pop culture's most loaded objects and turned it into a health-tracking accessory, which is either clever brand work or a costly bit of cosplay depending on execution. The company unveiled The One Ring, a limited-edition version of its Gen 3 Smart Ring, through a partnership with Warner Bros....

Continue Reading
PG&E's $456 Million Interim Hike Faces a New Test Soon

Updated Category News Views 198

A utility can call a charge interim, but households still see the bill arrive in full. That is why the California Public Utilities Commission's unanimous approval of $456 million in interim rate recovery for Pacific Gas & Electric has landed with such rotten timing. The money is set to begin flowing from customers on January 1, 2027, while major questions about PG&E's...

Continue Reading

Top 5 Most Recently Viewed Articles

Innovative Magnetron Solutions for Peak RF Performance

Updated Category News Views 129

Revolutionizing RF Power with Advanced Magnetron Transmitters In the realm of radio frequency (RF) technology, Diversified Technologies, Inc. (DTI) has unveiled a groundbreaking solid-state magnetron transmitter, which utilizes a novel Marx modulator. This innovative approach allows users to finely tune the pulse wave, enhancing overall performance and adaptability for...

Continue Reading
Lineage Inc. Strengthens Financial Agreements and Growth Potential

Updated Category News Views 142

Lineage Inc. Updates Financial Agreements for Greater Flexibility Lineage, Inc., a real estate investment trust recognized for its expertise in logistics, has made important changes to its financial agreements to bolster its financial standing. By adding more subsidiaries as obligors, the company demonstrates its flexibility and growth strategy. Recently, Lineage grabbed...

Continue Reading
Super League Achieves Major Financial Milestones in 2025

Updated Category News Views 394

Super League Reports Impressive Financial Growth Super League has recently showcased remarkable financial improvements, marking a significant turnaround in its operations. This comes on the heels of the company achieving a robust balance sheet powered by strategic investments, including a $20 million private placement and, notably, having zero debt. These developments not...

Continue Reading
Michael Lachmann's 'Spacetime Capsule' Documentary Now Streaming

Updated Category News Views 241

Michael Lachmann's Innovative Documentary Series The new documentary series, Spacetime Capsule, directed by British filmmaker Michael Lachmann, has recently premiered on popular Chinese video platforms. This captivating series, produced by China Review Studio, consists of three episodes that creatively employ the concept of a "spacetime capsule" to frame its narrative,...

Continue Reading
Innovative Leaders of Tomorrow: The 2025 TIME100 Next List

Updated Category News Views 395

TIME Introduces the Inspiring 2025 TIME100 Next List Tate McRae to Perform at the Upcoming TIME100 Next Event In a recent announcement, TIME has unveiled its exciting 2025 TIME100 Next list, spotlighting a diverse group of 100 emerging leaders from across the globe. These individuals are not only shaping the future but are also redefining leadership norms within their...

Continue Reading